DelveInsight’s “Chronic Obstructive Pulmonary Disease Pipeline Insight 2025” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Obstructive Pulmonary Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Obstructive Pulmonary Disease Treatment Landscape. Click here to read more @ Chronic Obstructive Pulmonary Disease Pipeline Outlook

Key Takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report

• In April 2025, Hoffmann-La Roche announced a study to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
• In April 2025, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. announced a Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
• In April 2025, AstraZeneca organized a phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).
• DelveInsight’s Chronic Obstructive Pulmonary Disease pipeline report depicts a robust space with 65+ active players working to develop 70+ pipeline therapies for Chronic Obstructive Pulmonary Disease treatment.
• The leading Chronic Obstructive Pulmonary Disease Companies such as Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, others.
• Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies such as QVA149, NVA237, Tiotropium, PF-00610355, Astegolimab, Formoterol Fumarate, TQC2731, Aclidinium bromide and others.

Discover groundbreaking developments in Chronic Obstructive Pulmonary Disease therapies! Gain in-depth knowledge of key Chronic Obstructive Pulmonary Disease clinical trials, emerging drugs, and market opportunities @ Chronic Obstructive Pulmonary Disease Clinical Trials Assessment

Chronic Obstructive Pulmonary Disease Emerging Drugs Profile

• Benralizumab: AstraZeneca

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG, which gives it a high affinity for the FcγRIIIα receptor in natural killer cells, macrophages, and neutrophils. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation, and migration to the lungs. The drug is currently in Phase III stage of its clinical trial evaluation to treat COPD.

• Dupilumab: Sanofi

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.

• Tezepelumab: Amgen

Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.

• SNG001: Synairgen

SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.

• GSK3923868: GlaxoSmithKline

GSK3923868, is a PI4kβ inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.

The Chronic Obstructive Pulmonary Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.
• Chronic Obstructive Pulmonary Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market

Stay informed about the Chronic Obstructive Pulmonary Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Obstructive Pulmonary Disease Unmet Needs

Chronic Obstructive Pulmonary Disease Companies

Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, others.

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide

Transform your understanding of the Chronic Obstructive Pulmonary Disease Pipeline! See the latest progress in drug development and clinical research @ Chronic Obstructive Pulmonary Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report

• Coverage- Global
• Chronic Obstructive Pulmonary Disease Companies- Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, Grifols Biologicals, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, others.
• Chronic Obstructive Pulmonary Disease Pipeline Therapies- QVA149, NVA237, Tiotropium, PF-00610355, Astegolimab, Formoterol Fumarate, TQC2731, Aclidinium bromide and others.
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Respiratory Diseases Research–Access the Full Chronic Obstructive Pulmonary Disease Pipeline Analysis Today! @ Chronic Obstructive Pulmonary Disease Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Obstructive Pulmonary Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tezepelumab: Amgen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GSK3923868: GlaxoSmithKline
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Obstructive Pulmonary Disease- Unmet Needs
21. Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight